Unresectable Gallbladder Cancer Completed Phase 2 Trials for Bevacizumab (DB00112)

IndicationStatusPhase
DBCOND0028792 (Unresectable Gallbladder Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00356889Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsTreatment